Provided by Tiger Trade Technology Pte. Ltd.

Haemonetics

106.60
-1.7200-1.59%
Post-market: 106.600.00000.00%19:50 EDT
Volume:661.28K
Turnover:70.71M
Market Cap:4.84B
PE:52
High:108.08
Open:107.75
Low:106.42
Close:108.32
52wk High:109.57
52wk Low:47.32
Shares:45.45M
Float Shares:44.60M
Volume Ratio:0.81
T/O Rate:1.48%
Dividend:- -
Dividend Rate:- -
EPS(TTM):2.05
EPS(LYR):2.05
ROE:11.20%
ROA:6.60%
PB:5.79
PE(LYR):52.00

Loading ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)

TIPRANKS
·
Aug 07

Haemonetics Price Target Raised to $96.00/Share from $84.00 by BTIG

Dow Jones
·
Aug 07

Haemonetics Corp Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Haemonetics' Fiscal Q1 Adjusted Earnings, Net Revenue Increase; Fiscal 2027 Outlook Raised

MT Newswires Live
·
Aug 06

Earnings Flash (HAE) Haemonetics Posts Fiscal Q1 Adjusted EPS $1.14, vs. FactSet Est of $0.87

MT Newswires Live
·
Aug 06

Haemonetics Q1 Adj. EPS $1.14 Beats $1.08 Estimate, Sales $339.380M Beat $327.894M Estimate

Benzinga Earnings
·
Aug 06

Haemonetics Outlook FY Organic Growth 4-7%

THOMSON REUTERS
·
Aug 06

Haemonetics Q1 Adjusted EPS USD 1.14 VS. Ibes Estimate USD 1.08

THOMSON REUTERS
·
Aug 06

Haemonetics FY27 Q1 Adjusted EPS Rises 3.6% to $1.14; Revenue Climbs 5.6% to $339.4 Million

Reuters
·
Aug 06

Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

THOMSON REUTERS
·
Aug 06

Haemonetics’ Vascade MVP system shows efficacy in electrophysiology study

TIPRANKS
·
Aug 04

Haemonetics Study Shows Vascade MVP XL Posts 1.2% Vascular Complications in 1,623 Large-Bore Electrophysiology Cases

Reuters
·
Aug 04

Earning Preview: Haemonetics revenue is expected to increase by 7.73%, and institutional views are moderately positive

Earnings Agent
·
Jul 31

Haemonetics price target raised to $93 from $80 at BofA

TIPRANKS
·
Jul 29

Haemonetics Adds Veteran Director as Shareholders Back Governance

TIPRANKS
·
Jul 29

Haemonetics Director Martin D. Madaus Files Initial Beneficial Ownership Statement

Reuters
·
Jul 29

Haemonetics Adds Carlyle Operating Executive Martin Madaus to Board

Reuters
·
Jul 29

Martin Madaus Elected to Haemonetics Board of Directors

THOMSON REUTERS
·
Jul 29

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

GlobeNewswire
·
Jul 22

Haemonetics Updates Financial Calendar with Q1 Fiscal 2027 Results Release and Earnings Call Scheduled

Reuters
·
Jul 09